Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML

Citations of this article
Mendeley users who have this article in their library.


Epigenetic changes can contribute to development of acute myeloid leukemia (AML), a malignant disease of the bone marrow. A single-nucleotide polymorphism of transcription factor growth factor independence 1 (GFI1) generates a protein with an asparagine at position 36 (GFI136N) instead of a serine at position 36 (GFI136S), which is associated with de novo AML in humans. However, how GFI136N predisposes to AML is poorly understood. To explore the mechanism, we used knock-in mouse strains expressing GFI136N or GFI136S. Presence of GFI136N shortened the latency and increased the incidence of AML in different murine models of myelodysplastic syndrome/AML. On a molecular level, GFI136N induced genomewide epigenetic changes, leading to expression of AML-associated genes. On a therapeutic level, use of histone acetyltransferase inhibitors specifically impeded growth of GFI136N-expressing human and murine AML cells in vitro and in vivo. These results establish, as a proof of principle, how epigenetic changes in GFI136N-induced AML can be targeted.




Botezatu, L., Michel, L. C., Helness, A., Vadnais, C., Makishima, H., Hönes, J. M., … Khandanpour, C. (2016). Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. Experimental Hematology, 44(8), 713-726.e14. https://doi.org/10.1016/j.exphem.2016.05.004

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free